These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 27305409)

  • 1. ANVISA APPROVES THE FIRST BIOSIMILAR MONOCLONAL ANTIBODY BASED ON COMPARABILITY IN BRAZIL.
    Teixeira FV; Kotze PG; Damião AO
    Arq Gastroenterol; 2016; 53(2):60-1. PubMed ID: 27305409
    [No Abstract]   [Full Text] [Related]  

  • 2. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilar infliximab for inflammatory bowel disease: from concepts to clinical practice. Case study illustrated with CT-P13.
    Schreiber S; Panés J; Kwon B; Hong S; Peyrin-Biroulet L
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():5-15. PubMed ID: 26395530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The scientific and regulatory rationale for indication extrapolation: a case study based on the infliximab biosimilar CT-P13.
    Reinisch W; Louis E; Danese S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():17-26. PubMed ID: 26395531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
    Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
    Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
    [No Abstract]   [Full Text] [Related]  

  • 6. Biosimilar infliximab: an expert view.
    Genazzani A; Altomare G; Balato N; Cusano F; De Pità O; Loconsole F; Micali G; Piaserico S; Girolomoni G
    G Ital Dermatol Venereol; 2015 Aug; 150(4):449-59. PubMed ID: 25747260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.
    Sieczkowska J; Jarzębicka D; Banaszkiewicz A; Plocek A; Gawronska A; Toporowska-Kowalska E; Oracz G; Meglicka M; Kierkus J
    J Crohns Colitis; 2016 Feb; 10(2):127-32. PubMed ID: 26721942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.
    Gecse KB; Lovász BD; Farkas K; Banai J; Bene L; Gasztonyi B; Golovics PA; Kristóf T; Lakatos L; Csontos ÁA; Juhász M; Nagy F; Palatka K; Papp M; Patai Á; Lakner L; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Szalay B; Molnár T; Lakatos PL
    J Crohns Colitis; 2016 Feb; 10(2):133-40. PubMed ID: 26661272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New frontiers in oncology: biosimilar monoclonal antibodies for the treatment of breast cancer.
    Thill M
    Expert Rev Anticancer Ther; 2015 Mar; 15(3):331-8. PubMed ID: 25539719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biosimilars: in support of extrapolation of indications.
    Ebbers HC
    J Crohns Colitis; 2014 May; 8(5):431-5. PubMed ID: 24594005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An update on biosimilar drugs for inflammatory bowel disease.
    Schreiber S
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():1-3. PubMed ID: 26395529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scientific rationale behind the development and approval of biosimilar infliximab (CT-P13) in Europe.
    Müller-Ladner U; Hong S; Oh C; Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S5-14. PubMed ID: 26395832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter: is there a role for infliximab biosimilar in patients with inflammatory bowel disease with secondary loss of response to infliximab innovator?
    Orfanoudaki E; Drygiannakis I; Koutroubakis IE
    Aliment Pharmacol Ther; 2018 Nov; 48(9):1037-1038. PubMed ID: 30318690
    [No Abstract]   [Full Text] [Related]  

  • 14. Biosimilars in inflammatory bowel diseases: an important moment for Brazilian gastroenterologists.
    Teixeira FV; Kotze PG; Damião AO; Miszputen SJ
    Arq Gastroenterol; 2015; 52(1):76-80. PubMed ID: 26017088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflectra - an infliximab biosimilar.
    Med Lett Drugs Ther; 2017 Jan; 59(1513):23-25. PubMed ID: 28118651
    [No Abstract]   [Full Text] [Related]  

  • 16. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.
    Danese S; Fiorino G; Michetti P
    J Crohns Colitis; 2014 Nov; 8(11):1548-50. PubMed ID: 25008477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Infliximab biosimilar CT-P13 for inflammatory bowel disease.
    Bonovas S; Peyrin-Biroulet L; Danese S
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):373-375. PubMed ID: 29606565
    [No Abstract]   [Full Text] [Related]  

  • 18. [First biosimilar infliximab approved].
    Neumaier J
    MMW Fortschr Med; 2015 Mar; 157 Suppl 1():88. PubMed ID: 26013000
    [No Abstract]   [Full Text] [Related]  

  • 19. Progress in biosimilar monoclonal antibody development: the infliximab biosimilar CT-P13 in the treatment of rheumatic diseases.
    Braun J; Kudrin A
    Immunotherapy; 2015; 7(2):73-87. PubMed ID: 25713985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: CT-P13, a biosimilar of anti-tumour necrosis factor-alpha agent (infliximab), in inflammatory bowel diseases.
    Felwick R; Cummings JRF
    Aliment Pharmacol Ther; 2017 May; 45(10):1370-1371. PubMed ID: 28417492
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.